A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Latest Information Update: 15 May 2023
At a glance
- Drugs Darolutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PEACE6-Unfit
- 21 Feb 2022 Planned End Date changed from 1 Jul 2032 to 1 Sep 2033.
- 21 Feb 2022 Planned primary completion date changed from 1 Dec 2027 to 1 Mar 2028.
- 21 Feb 2022 Planned initiation date changed from 1 Dec 2021 to 1 Mar 2022.